GlassScriptPhysician profile
Stacy L Konyar
NPI 1972806404
$45,438.69
in general payments reported to CMS, 2019-2025
56 companies · $2,579 in 2025
The $2,579 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $16K · 2023: $6,260 · 2024: $2,322 · 2025: $2,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,925 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,988 · Education: $189 · Travel and Lodging: $60.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,924.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,987.50 |
| Education | $188.99 |
| Travel and Lodging | $60.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,760.10 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $9,559.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,345.51 | 2022 | |
| Allergan, INC. | $2,589.20 | 2021-2022 | |
| Lilly USA, LLC | $1,048.94 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Biogen, INC. | $1,034.31 | 2021-2022 | |
| Pfizer INC. | $943.36 | 2021-2025 | |
| Novo Nordisk INC | $835.21 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $605.20 | 2023-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $502.13 | 2021-2023 | Ajovy |
| Astrazeneca Pharmaceuticals LP | $338.81 | 2024-2025 | Airsupra, Breztri |
| Abbott Laboratories | $329.63 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $309.00 | 2023-2025 | Auvelity, Sunosi |
| Alexion Pharmaceuticals, INC. | $287.61 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $278.19 | 2021-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Konyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.